Browsing by Author "Nathan, Cherie-Ann O."

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Concerns and Needs of Patients With Head and Neck Cancer in the COVID-19 Era
    (Sage, 2021-07) Yan, Flora; Rauscher, Erika; Hollinger, Amanda; Caputo, Mary Ann; Ready, John; Nguyen, Shaun A.; Fakhry, Carole; Nathan, Cherie-Ann O.; Leonardis, Chris; Yearout, Danielle; Day, Terry A.; Moore, Michael G.; Otolaryngology -- Head and Neck Surgery, School of Medicine
    Objective: To evaluate the concerns and needs of patients and survivors of head and neck cancer (HNC) in the COVID-19 era. Study Design: Prospective cross-sectional survey. Setting: Contact lists of 5 North American HNC advocacy groups. Methods: A 14-question survey was distributed to the contact lists of 5 HNC advocacy groups evaluating patient and survivor needs and concerns related to their cancer care and COVID-19. Results: There were 171 respondents, with 75% in the posttreatment period. The most common concern was contraction of COVID-19 (49%). More patients in active treatment preferred in-person visits than those in the early (≤5 years) and late (>5) survivorship period (72% vs 61% vs 40%, P < .001). A higher percentage of late survivors preferred virtual visits (38% vs 28%, P = .001). In total, 91 (53.2%) respondents sought emotional support outside of immediate family and friends. This included cancer support groups (36.2%), the medical team (29.7%), and other sources outside of these (34.1%), including faith-based organizations and online communities. A higher proportion of women than men (62% vs 41%, P = .001) were seeking emotional support outside of immediate family and friends. Conclusions: During the early stages of the COVID-19 pandemic, patients with HNC who were actively undergoing treatment had increased need for support resources and preferred in-person provider visits. Alternatively, a higher percentage of patients >5 years from treatment preferred virtual visits. Emotional support outside of family and friends was sought out by a majority of respondents. Further research is needed to determine what support and educational resources are needed to best aid these various populations.
  • Thumbnail Image
    Item
    Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment
    (Frontiers Media, 2024-04-12) Gundle, Kenneth R.; Rajasekaran, Karthik; Houlton, Jeffrey; Deutsch, Gary B.; Ow, Thomas J.; Maki, Robert G.; Pang, John; Nathan, Cherie-Ann O.; Clayburgh, Daniel; Newman, Jason G.; Brinkmann, Elyse; Wagner, Michael J.; Pollack, Seth M.; Thompson, Matthew J.; Li, Ryan J.; Mehta, Vikas; Schiff, Bradley A.; Wenig, Barry I.; Swiecicki, Paul L.; Tang, Alice L.; Davis, Jessica L.; van Zante, Annemieke; Bertout, Jessica A.; Jenkins, Wendy; Turner, Atticus; Grenley, Marc; Burns, Connor; Frazier, Jason P.; Merrell, Angela; Sottero, Kimberly H. W.; Derry, Jonathan M. J.; Gillespie, Kate C.; Mills, Bre; Klinghoffer, Richard A.; Pathology and Laboratory Medicine, School of Medicine
    Introduction: Drug development is systemically inefficient. Research and development costs for novel therapeutics average hundreds of millions to billions of dollars, with the overall likelihood of approval estimated to be as low as 6.7% for oncology drugs. Over half of these failures are due to a lack of drug efficacy. This pervasive and repeated low rate of success exemplifies how preclinical models fail to adequately replicate the complexity and heterogeneity of human cancer. Therefore, new methods of evaluation, early in the development trajectory, are essential both to rule-in and rule-out novel agents with more rigor and speed, but also to spare clinical trial patients from the potentially toxic sequelae (high risk) of testing investigational agents that have a low likelihood of producing a response (low benefit). Methods: The clinical in vivo oncology (CIVO®) platform was designed to change this drug development paradigm. CIVO precisely delivers microdose quantities of up to 8 drugs or combinations directly into patient tumors 4–96 h prior to planned surgical resection. Resected tissue is then analyzed for responses at each site of intratumoral drug exposure. Results: To date, CIVO has been used safely in 6 clinical trials, including 68 subjects, with 5 investigational and 17 approved agents. Resected tissues were analyzed initially using immunohistochemistry and in situ hybridization assays (115 biomarkers). As technology advanced, the platform was paired with spatial biology analysis platforms, to successfully track anti-neoplastic and immune-modulating activity of the injected agents in the intact tumor microenvironment. Discussion: Herein we provide a report of the use of CIVO technology in patients, a depiction of the robust analysis methods enabled by this platform, and a description of the operational and regulatory mechanisms used to deploy this approach in synergistic partnership with pharmaceutical partners. We further detail how use of the CIVO platform is a clinically safe and scientifically precise alternative or complement to preclinical efficacy modeling, with outputs that inform, streamline, and de-risk drug development.
  • Thumbnail Image
    Item
    The role of head and neck cancer advocacy organizations during the COVID-19 pandemic
    (Wiley, 2020-05-29) Yan, Flora; Rauscher, Erika; Hollinger, Amanda; Caputo, Mary Ann; Ready, John; Fakhry, Carole; Nathan, Cherie-Ann O.; Leonardis, Chris; Yearout, Danielle; Tsue, Terance T.; Day, Terry A.; Moore, Michael G.; Otolaryngology -- Head and Neck Surgery, School of Medicine
  • Thumbnail Image
    Item
    The role of head and neck cancer advocacy organizations during the COVID-19 pandemic
    (Wiley, 2020-07) Yan, Flora; Rauscher, Erika; Hollinger, Amanda; Caputo, Mary Ann; Ready, John; Fakhary, Carole; Nathan, Cherie-Ann O.; Leonardis, Chris; Yearout, Danielle; Tsue, Terance T.; Day, Terry A.; Moore, Michael G.; Otolaryngology -- Head and Neck Surgery, School of Medicine
    The COVID‐19 pandemic has had a significant impact on many aspects of head and neck cancer (HNC) care. The uncertainty and stress resulting from these changes has led many patients and caregivers to turn to HNC advocacy groups for guidance and support. Here we outline some of the issues being faced by patients with HNC during the current crisis and provide examples of programs being developed by advocacy groups to address them. We also highlight the increased utilization of these organizations that has been observed as well as some of the challenges being faced by these not‐for‐profit groups as they work to serve the head and neck community.
  • Thumbnail Image
    Item
    We Survived 2020 With Patient Survivors: Presidential Address
    (AMA, 2020-11) Nathan, Cherie-Ann O.; Fakhry, Carole; Moore, Michael G.; Otolaryngology -- Head and Neck Surgery, School of Medicine